Medtech firm Integra's Q2 revenue beats expectations

Integra LifeSciences Holdings

31/07/2025 11:08

Overview

Integra Q2 revenue of $415.6 mln beats analyst expectations, per LSEG data

Adjusted EPS for Q2 at $0.45, exceeding analyst estimates, per LSEG data

GAAP net loss driven by $511 mln goodwill impairment charge

Outlook

Company expects Q3 revenue between $410 mln and $420 mln

Integra Lifesciences sees Q3 adjusted EPS of $0.40 to $0.45

Company updates full-year revenue guidance to $1.655 bln to $1.680 bln

Integra reaffirms full-year adjusted EPS guidance of $2.19 to $2.29

Result Drivers

GOODWILL IMPAIRMENT - $511 mln charge due to stock price drop from tariff changes and operational issues

NEUROSURGERY DEMAND - Strong demand for neurosurgery products like CUSA and Aurora, offset by shipping holds

SUPPLY CHAIN ISSUES - Private label sales down due to component supply delays and softer demand

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$415.60 mln
$395.10 mln (10 Analysts)
Q2 Adjusted EPS
Beat
$0.45
$0.43 (10 Analysts)
Q2 EPS
-$6.31
Q2 Adjusted Net Income
$34.40 mln
Q2 Adjusted EBITDA
$71.20 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and 4 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Integra Lifesciences Holdings Corp is $13.00, about 4.8% above its July 30 closing price of $12.37

The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nGNXc1rHdX

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)